Nigeria Pharma Shift: Local Drug Production Jumps from 30% to 50% as Regulatory Reforms Drive Six-Fold Manufacturing Growth

**TL;DR**: Nigeria has reversed its pharmaceutical import dependence, moving from 70% imported drugs to 50% locally manufactured in recent years, driven by stricter regulations and government incentives.

Nigeria's pharmaceutical sector has undergone a fundamental shift. For decades, imported medicines dominated the market, with the import-to-local manufacturing ratio standing at 70:30. That equation has now flipped to approximately 50:50, marking a major reversal in domestic production.

The transformation stems from deliberate government policies and stronger regulatory oversight. The National Agency for Food and Drug Administration and Control (NAFDAC) required manufacturers to either migrate to local production or partner with Nigerian firms. The result: approximately a six-fold increase in local manufacturing capacity.

"No investor would like to invest where the regulatory system is weak," said NAFDAC Director-General Prof. Mojisola Adeyeye at the commissioning of a new SAM Pharmaceuticals facility in Ogun State. She credited the "five-plus-five" policy and "ceiling list" framework for enabling this expansion.

The reforms come with tangible incentives. Eighty-seven local manufacturers currently benefit from the Presidential Executive Order, which includes zero tariffs on pharmaceutical machinery and raw materials. Two Nigerian products have achieved WHO prequalification, opening pathways to international markets.

NAFDAC has already attained World Health Organisation Maturity Level 3 status and is now targeting Level 4 and eventual World Listed Authority recognition. Higher global regulatory ratings would grant Nigerian pharmaceutical products access to international markets.

Plans are also advancing for local production of Active Pharmaceutical Ingredients (APIs), the raw materials used in drug manufacturing. Currently, Nigeria imports most APIs, making local production a key milestone for the sector's independence.

The growth extends beyond numbers. New factories are emerging, existing facilities are expanding, and contract manufacturing has grown six-fold. Ogun State has become a particular hub, with several new pharmaceutical investments announced.

What to watch next: whether Nigeria can sustain this trajectory and achieve its goal of becoming a regional pharmaceutical export hub.